Efficacy : Supply water, electrolytes, amino acids, calories, essential fatty acids and omega-3 fatty acids to patients who needs nutrition supply through jugular vein due to limitations or insufficiency or impossible nutrition supply through oral or gastrointestinal means. 1. Easy to mix with 3CB All-in-one method, less risk of contamination and error, and possible supply of all nutrients (amino acids, glucose, lipids and electrolytes) as a stand alone product. 2. Supplies energy with mixture of 1:1 LCT and MCT and does not affect liver function.

Efficacy : Supply water, electrolytes, amino acids, calories, essential fatty acids and omega-3 fatty acids to patients who need nutrition supply through jugular vein due to limitations or insufficiency, or impossible nutrition supply through oral or gastrointestinal means. 1. Contains the nation's highest content of fish oil and builds optimal concentrations in anti-inflammatory and immune function with ratio 2.1:1 of ω-6:ω-3. 2. Suitable drug with high content of amino acids for chain protein synthesis in severe patients. 3. Glucose and fat calorie is in compliance with ESPEN guideline (50:50~57:43). 4. Increases immune system and antioxidant capacity of patient by mixing Zn and tocopherol.

Efficacy :Neutropenia of patients receiving chemotherapy for solid cancer and hematolic malignancies;neutropenia due to myelodysplastic syndrome; neutropenia due to aplstic anemia; congenital idiopathic neutropenia; neutropenia that affects Human Immunodeficiency Virus (HIV) infection treatment; neutropenia due to immunosuppressive therapy (renal transplantation); peripheral blood mobilization of hematopoietic stem cells; promote neutrophil increase of hematopoietic stem cell transplantation Enhanced safety and efficacy of G-CSF drug with glycan Better potency than the competing product Grasin in PBSCT (peripheral stem cell transplantation)

Efficacy : Primary hypercholesterolemia and dyslipidemia Superstatin reduces LDL-C and increases HDL-C, proven to be effective in preventing the occurrence of diabetes with J-Precict clinical trials. Minimizes risks of drug interactions when co-administrered with CYP450.